Cancer Genetics ROE

Mitä Cancer Genetics tekee? Cancer Genetics Inc (CGI) is a biotechnology company specialized in genetic cancer research since 1999. The company is headquartered in Rutherford, New Jersey, USA and listed on NASDAQ under the ticker symbol CGIX. CGI focuses on the development of diagnostic tests and procedures to identify genetic mutations associated with various types of cancer. CGI was initially founded as NeoGenomics in Florida. In 2000, the company underwent a restructuring, shifting its focus to cancer diagnostics and prognosis. The following year, it changed its name to Cancer Genetics Inc and relocated to Rutherford, New Jersey. The business model of CGI revolves around creating diagnostic tests and services for cancer detection and prognosis based on the genetic foundation of cancer. The company identifies changes in the DNA, RNA, and proteins of cancer cells, enabling predictions about tumor behavior and patient response to specific treatments. CGI's portfolio includes four business sectors: Clinical Services, Pharma Services, Discovery Services, and BioPharma. In the clinical services sector, the company offers various services such as diagnostic tests, sample analysis, and pathology testing. This includes CGH microarray for identifying DNA changes, FISH test for detecting specific tumor driver mutations, as well as immunohistology and molecular diagnostics. In the Pharma Services business, CGI provides extensive services related to clinical studies, including sample management, biomarker identification, and laboratory-based services like patient recruitment and profiling, protocol development, and criteria for participating in clinical trials. The Discovery Services sector offers support to companies in preclinical research, involving the identification and validation of biomarkers and target molecules that can be used in the development of new therapies and drugs for cancer. Finally, the BioPharma sector offers services related to partnerships in the development of oncology products. CGI collaborates with larger pharmaceutical companies to identify and conduct clinical trials, as well as develop diagnostic tests and personalized medications for cancer treatment. CGI also offers a range of medical products, including diagnostic tests like the Tissue of Origin test to identify the source of cancer cells, OncoGenius and FISHpath for identifying oncogenic triggers in cancer cells, and TargetSNP, a genetic test to identify polymorphisms associated with responsiveness to certain cancer drugs. In summary, CGI is a publicly traded biotechnology company specialized in developing diagnostic tests and procedures to identify genetic mutations associated with various types of cancer. The company provides services in different areas of cancer research, from clinical diagnostics to partnering in the development of cancer medications. Their product portfolio includes a variety of diagnostic tests for identifying cancer triggers. CGI aims to become a leading company in cancer research and contribute significantly to the development of new and effective treatments for cancer patients. Cancer Genetics on yksi Eurpooliin suosituimmista yhtiöistä.